Here's a look at our competition: From Medscape Medical News:
Monoclonal Antibody Combo Treatment Reduces Viral Load in Mild-to-Moderate COVID
Marcia Frellick
January 21, 2021
A combination treatment of neutralizing monoclonal antibodies bamlanivimab and etesevimab was associated with a statistically significant reduction in SARS-CoV-2 at day 11 compared with placebo among nonhospitalized patients who had mild-to-moderate COVID-19, new data indicate.
However, bamlanivimab alone in three different single-infusion doses showed no significant reduction in viral load compared with placebo, according to the phase 2/3 study by Robert L. Gottlieb, MD, PhD, of the Baylor University Medical Center and the Baylor Scott & White Research Institute in Dallas, Texas, and colleagues.
Separately, in a press release today, Eli Lilly, which makes both antispike neutralizing antibodies, says bamlanivimab helps prevent illness among nursing home residents according to data from a trial.
Findings from the Blocking Viral Attachment and Cell Entry with SARS-CoV-2 Neutralizing Antibodies (BLAZE-1) study were published online today in JAMA. The results represent findings through October 6, 2020.
BLAZE-1, which was funded by Eli Lilly and Company, was conducted at 49 US centers and included 613 outpatients who tested positive for SARS-CoV-2 and had one or more mild-to-moderate symptoms.
Patients were randomized to one of five groups (four treatment groups and a placebo control), and researchers analyzed between-group differences.
All four treatment arms suggest a trend toward reduction in viral load, which was the primary endpoint of the trial, but only the combination showed a statistically significant reduction.